Purple Biotech Ltd

Healthcare · Biotechnology · Israel

Last price 1.17 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 10.49M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin recept...